



ADAMA

## Adama Licenses Starpharma's Priostar for Novel 2,4-D

**Melbourne, Australia and Tel-Aviv, Israel; 17 March, 2016** – Starpharma (ASX:SPL; OTCQX: SPHRY) and Adama today announced the licensing by Adama of Starpharma's Priostar<sup>®</sup> dendrimer technology for the development and commercialization of an enhanced, proprietary 2,4-D herbicide for the US market. 2,4-D is one of the top three herbicides sold world-wide, with global sales in 2014 estimated by Phillips McDougall to be around US\$680 million. The US market in 2014 was worth approximately US\$115 million, and has been projected by the US Department of Agriculture to grow by more than 70% by 2020.

Adama has already undertaken development of a novel and unique 2,4-D product containing the Priostar<sup>®</sup> dendrimer technology, which is expected to provide better flexibility and weed control benefits to the grower, as well as improved safety. This will allow for on-target application, thus benefiting the environment by reducing the amounts of product required.

Under the license, Starpharma will receive royalties on sales of the proprietary Adama Priostar<sup>®</sup>-improved 2,4-D products. In addition to the US, the agreement also includes a mechanism to expand the license into additional territories.

**Sami Shabtai, Head of Innovative Development at Adama**, commented, "As a farmer-centric company, Adama constantly strives to bring new and innovative solutions to farmers that will simplify their lives. The innovative nature and superior performance of the Priostar<sup>®</sup> formulations fit well with our strategy to deliver simple and efficient solutions to farmers to help them grow. This is yet another step in the evolution and differentiation of our offering, as we continue to introduce unique mixtures and formulations to the market."

**Dr. Jackie Fairley, CEO of Starpharma**, said, "We enjoy a positive relationship with Adama, and their extensive trials of Priostar<sup>®</sup>-improved 2,4-D formulations have led to this license agreement. With Adama's strong, proven record of innovative product development, we are very pleased to have them as commercial partners for Priostar<sup>®</sup>-improved 2,4-D products. In addition, we continue to explore other Priostar<sup>®</sup> product opportunities with Adama."

## ABOUT PRIOSTAR® DENDRIMERS

Starpharma's Priostar® dendrimer technology offers formulation and efficacy benefits in crop protection applications including:

- Improved efficacy
- More concentrated formulations to reduce transport costs;
- Reduction in solvent requirements; and
- Increased adhesion, to reduce losses due to rain run-off, and the need for multiple applications.

## ABOUT ADAMA

### **ADAMA Agricultural Solutions Ltd.:**

Adama is one of the world's leading crop protection companies. We strive to Create Simplicity in Agriculture – providing farmers with easy-to-use and effective solutions that simplify their lives and help them grow. With one of the most comprehensive portfolios of differentiated, high-quality products, Adama's 4,800 people reach farmers in over 120 countries across the globe, offering them solutions and services to control weeds, insects and disease that harm their crops. For more information, visit us at [www.adama.com](http://www.adama.com).

## ABOUT STARPHARMA

Starpharma Holdings Limited, an Australian ASX 300 company, is a world leader in the development of novel products based on dendrimers, a type of synthetic nanoscale polymer that is highly regular in size and structure, for pharmaceutical, life science and other applications. Starpharma has three core development programs: VivaGel® portfolio, DEP™ drug delivery, and agrochemicals with a number of products being developed internally and externally via commercial partnerships. Partners include AstraZeneca, Ansell, and Okamoto, as well as other named and undisclosed partnerships with leading global companies in pharmaceuticals and agrochemicals. For more information please visit: [www.starpharma.com](http://www.starpharma.com)

## FOR FURTHER INFORMATION

### **Media:**

#### **Buchan Consulting**

Rebecca Wilson

Mob: +61 417 382 391

[rwilson@buchanwe.com.au](mailto:rwilson@buchanwe.com.au)

Gabriella Hold

+61 3 9866 4722

[ghold@buchanwe.com.au](mailto:ghold@buchanwe.com.au)

#### **Starpharma:**

Dr Jackie Fairley, Chief Executive Officer

Nigel Baade, CFO and Company Secretary

+61 3 8532 2704

[investor.relations@starpharma.com](mailto:investor.relations@starpharma.com)

[www.starpharma.com](http://www.starpharma.com)

---

### Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.